Deaths, accusations of insider trading and an early warning from Boehringer stir Hanmi controversy
Controversy over a lethal cancer drug developed by Hanmi and Boehringer Ingelheim continues to bubble up in Korea.
In recent days a member of the opposition Minjoo party — Rep. Jung Choun-sook — circulated a letter from Boehringer Ingelheim dating back to August 23rd stating that they were halting enrollment and studies of olmutinib at the recommendation of the Data Monitoring Committee, according to a report in the Korea Herald. And he accused the country’s food and drug safety ministry of allowing trials to continue even after the dangers became apparent.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.